Sarepta Therapeutics Inc. [NASDAQ: SRPT] closed the trading session at $82.29 on 01/08/21. The day’s price range saw the stock hit a low of $82.25, while the highest price level was $88.4799. The company report on January 10, 2021 that SRPT Investor Alert – Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sarepta Therapeutics, Inc. Investigation.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
The investigation concerns whether Sarepta and certain of its officers and/or directors have violated federal securities laws.
The stocks have a year to date performance of -51.73 percent and weekly performance of -51.73 percent. The stock has been moved at -51.25 percent over the last six months. The stock has performed -47.52 percent around the most recent 30 days and changed -43.13 percent over the most recent 3-months.
If compared to the average trading volume of 787.90K shares, SRPT reached to a volume of 22521215 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Sarepta Therapeutics Inc. [SRPT]:
Raymond James have made an estimate for Sarepta Therapeutics Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on January 08, 2021. The new note on the price target was released on January 08, 2021, representing the official price target for Sarepta Therapeutics Inc. stock. Previously, the target price had yet another raise to $96, while JP Morgan analysts kept a Underweight rating on SRPT stock.
The Average True Range (ATR) for Sarepta Therapeutics Inc. is set at 12.86, with the Price to Sales ratio for SRPT stock in the period of the last 12 months amounting to 26.93. The Price to Book ratio for the last quarter was 7.24, with the Price to Cash per share for the same quarter was set at 11.21. Price to Free Cash Flow for SRPT in the course of the last twelve months was 281.28 with Quick ratio for the last quarter at 5.60.
SRPT stock trade performance evaluation
Sarepta Therapeutics Inc. [SRPT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -51.73. With this latest performance, SRPT shares dropped by -47.52% in over the last four-week period, additionally sinking by -51.25% over the last 6 months – not to mention a drop of -37.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SRPT stock in for the last two-week period is set at 15.77, with the RSI for the last a single of trading hit 9.42, and the three-weeks RSI is set at 21.69 for Sarepta Therapeutics Inc. [SRPT]. The present Moving Average for the last 50 days of trading for this stock 151.02, while it was recorded at 149.45 for the last single week of trading, and 144.60 for the last 200 days.
Sarepta Therapeutics Inc. [SRPT]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sarepta Therapeutics Inc. [SRPT] shares currently have an operating margin of -137.10 and a Gross Margin at +84.92. Sarepta Therapeutics Inc.’s Net Margin is presently recorded at -187.77.
Return on Total Capital for SRPT is now -34.71, given the latest momentum, and Return on Invested Capital for the company is -47.66. Return on Equity for this stock declined to -77.29, with Return on Assets sitting at -41.28. When it comes to the capital structure of this company, Sarepta Therapeutics Inc. [SRPT] has a Total Debt to Total Equity ratio set at 90.13. Additionally, SRPT Total Debt to Total Capital is recorded at 47.41, with Total Debt to Total Assets ending up at 40.46. Long-Term Debt to Equity for the company is recorded at 89.18, with the Long-Term Debt to Total Capital now at 46.90.
Reflecting on the efficiency of the workforce at the company, Sarepta Therapeutics Inc. [SRPT] managed to generate an average of -$962,416 per employee. Receivables Turnover for the company is 4.81 with a Total Asset Turnover recorded at a value of 0.22.Sarepta Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.60 and a Current Ratio set at 6.10.
Earnings per share (EPS) analysis for Sarepta Therapeutics Inc. [SRPT] stock
With the latest financial reports released by the company, Sarepta Therapeutics Inc. posted -3.16/share EPS, while the average EPS was predicted by analysts to be reported at -1.86/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -69.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SRPT.
Sarepta Therapeutics Inc. [SRPT]: Insider Ownership positions
There are presently around $5,819 million, or 92.60% of SRPT stock, in the hands of institutional investors. The top three institutional holders of SRPT stocks are: VANGUARD GROUP INC with ownership of 7,091,182, which is approximately -0.373% of the company’s market cap and around 4.50% of the total institutional ownership; CAPITAL RESEARCH GLOBAL INVESTORS, holding 6,711,324 shares of the stock with an approximate value of $552.27 million in SRPT stocks shares; and FMR LLC, currently with $522.02 million in SRPT stock with ownership of nearly -18.929% of the company’s market capitalization.
Positions in Sarepta Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 184 institutional holders increased their position in Sarepta Therapeutics Inc. [NASDAQ:SRPT] by around 6,769,698 shares. Additionally, 194 investors decreased positions by around 8,866,941 shares, while 74 investors held positions by with 55,081,000 shares. The mentioned changes placed institutional holdings at 70,717,639 shares, according to the latest SEC report filing. SRPT stock had 50 new institutional investments in for a total of 682,338 shares, while 53 institutional investors sold positions of 1,314,765 shares during the same period.